BVF is a specialized healthcare hedge fund with a track record of deep-value biotech investing. While this is a passive 13G, the 8.4% aggregate stake (including managed accounts) signals conviction. Monitor for any future conversion to a 13D or public engagement, which would indicate a shift toward activism. For now, the filing is a neutral data point reflecting institutional accumulation.
Price Chart
Executive Summary
Biotechnology Value Fund L.P. (BVF), a dedicated healthcare hedge fund, filed a new Schedule 13G disclosing a 7.7% beneficial ownership stake in Alector, Inc. as of September 18, 2026. The filing is passive (Rule 13d-1(c)), indicating no intent to influence control. This is a new position for BVF, which previously did not appear in the cross-filed SC 13G/A from Polaris or the BlackRock SC 13G. The stake is notable for its size and the fund's biotech focus, but as a passive filing, it does not signal activist intent.
Key Financial Metrics
Key Facts
- Biotechnology Value Fund L.P. (BVF) and related entities filed a new Schedule 13G on September 18, 2026.
- BVF GP Holdings LLC (the top holding entity) beneficially owns 8,571,159 shares, representing 7.7% of Alector's outstanding common stock.
- BVF Partners L.P., BVF Inc., and Mark N. Lampert each may be deemed to beneficially own 9,374,267 shares (8.4%), which includes shares held in a managed account.
- The filing is made under Rule 13d-1(c) — a passive investor statement with no intent to change or influence control.
- The percentage calculations are based on 111,656,919 shares outstanding as of July 31, 2026 (per Alector's Form 10-Q filed August 6, 2026).
- This is a new position; BVF did not appear in prior SC 13G filings for Alector (Polaris Venture Partners and BlackRock were the prior filers).
Financial Impact
BVF's aggregate stake of 9,374,267 shares (8.4% beneficial ownership) represents a significant passive position in a clinical-stage biotech. No transaction values are disclosed in the filing.
Risk Factors
- BVF could convert to a 13D and become activist, potentially pushing for strategic changes (e.g., pipeline prioritization, M&A).
- Alector's stock may face selling pressure if BVF decides to reduce its position, given the size of the stake relative to daily volume.
- The passive filing does not preclude BVF from engaging privately with management, which could lead to undisclosed discussions.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000921895-26-002587 |
| Document: 0000921895-26-002587-index-headers.html | 0000921895-26-002587 |
| Document: 0000921895-26-002587-index.html | 0000921895-26-002587 |
| Document: 0000921895-26-002587.txt | 0000921895-26-002587 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | — | awaiting T+60 | — | — |
Oct 23, 2026 3d ago | SC 13G | $1.84 | awaiting T+60 | — | $1.83 (−0.33%) |
Oct 16, 2026 10d ago | 424B5 | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 16, 2026 10d ago | 8-K | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 14, 2026 12d ago | 8-K | $1.88 | awaiting T+60 | — | $1.83 (−2.66%) |
Oct 5, 2026 21d ago | 8-K | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Oct 5, 2026 21d ago | Press Release | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Sep 18, 2026 5w ago | SC 13G | $1.93 | awaiting T+60 | — | $1.83 (−5.18%) |
Sep 4, 2026 7w ago | Insider Cluster | $2.47 | awaiting T+60 | — | $1.83 (−25.91%) |
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 | awaiting T+60 | — | $1.83 (−10.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers